The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Objective response rate (ORR) and time to treatment failure (TTF) for BRAF v600 mutated metastatic melanoma (BRAF+ MM) patients receiving first-line (1L) treatment with dabrafenib/trametinib (D+T) v ipilimumab/nivolumab (I+N) and nivolumab or pembrolizumab (N/P) monotherapy at US-based community oncology practices.
 
Bruce A. Feinberg
No Relationships to Disclose
 
Jonathan Kish
Employment - Cardinal Health
Research Funding - Novartis (Inst)
 
Sameer R. Ghate
Employment - Novartis
Stock and Other Ownership Interests - Agenus (I); Bluebird Bio; Dynavax Technologies (I); Exelixis (I); Juno Therapeutics; Mannkind; Newlink Genetics (I); Novartis; Provectus
 
Briana Ndife
Employment - Novartis
Research Funding - Novartis; Novartis
 
Choo Hyung Lee
Employment - Cardinal Health
 
Lindsay McAllister
Employment - Cardinal Health
 
Sonam Mehta
Employment - Cardinal Health
 
Antonio Reis Nakasato
Employment - Celgene (I); Novartis
Stock and Other Ownership Interests - Celgene; Corbus Pharmaceuticals; Incyte; Nektar; Novartis; OncoSec
 
Jason J. Luke
Honoraria - Intellisphere, LLC
Consulting or Advisory Role - 7 Hills Pharma; Actym Therapeutics; Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; Janssen; Merck; Newlink Genetics; Novartis; Reflexion Medical; Syndax; Tempest Therapeutics
Research Funding - Abbvie; Boston Biomedical; Bristol-Myers Squibb; Celldex; Checkmate Pharmaceuticals; Corvus Pharmaceuticals; Delcath Systems; Five Prime Therapeutics; Genentech/Roche; Immunocore; Incyte; Macrogenics; MedImmune; Merck; Novartis; Palleon Pharmaceuticals; Pharmacyclics; Tesaro
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; Janssen; Merck; Novartis; Reflexion Medical